CRISPR Therapeutics AG (CRSP.O)

+ 收藏

现金流量表(CRISPR Therapeutics AG)

导出到EXCEL
报表日期选择
  • 常用日期查询
  • 自定义年度查询
    日期范围
    报告期
    报告类型
    显示选项
关 闭
完整财报对比
2025年中报2025年一季报2024年年报2024年三季报2024年中报2024年一季报2023年年报2023年三季报2023年中报2023年一季报
起始日期 2025-01-012025-01-012024-01-012024-01-012024-01-012024-01-012023-01-012023-01-012023-01-012023-01-01
报表类型 合并报表合并报表合并报表合并报表合并报表合并报表合并报表合并报表合并报表合并报表
报表年结日 1231123112311231123112311231123112311231
原始币种 美元美元美元美元美元美元美元美元美元美元
上市前/上市后 上市后上市后上市后上市后上市后上市后上市后上市后上市后上市后
经营活动产生的现金流量:
 净利润(元) 会员可见会员可见会员可见会员可见-242,999,000.00-116,591,000.00-153,610,000.00-242,957,000.00-130,805,000.00-53,065,000.00
 折旧及摊销(元) 会员可见会员可见会员可见会员可见9,678,000.004,833,000.0019,837,000.0014,937,000.0010,012,000.005,051,000.00
 基于股票的补偿费(元) 会员可见会员可见会员可见会员可见43,077,000.0019,405,000.0081,028,000.0062,608,000.0042,640,000.0020,875,000.00
 经营业务调整其他项目(元) 会员可见会员可见会员可见会员可见-16,566,000.00-8,385,000.00-14,045,000.00-9,279,000.00-4,120,000.00-969,000.00
 预付款项及其他应收款减少(增加)(元) 会员可见会员可见会员可见会员可见5,297,000.002,949,000.0023,219,000.0016,769,000.0015,952,000.0012,040,000.00
 应收账款及票据减少(增加)(元) 会员可见会员可见会员可见会员可见200,000,000.00200,000,000.00-200,000,000.00--70,000,000.00-
 应付账款及票据增加(减少)(元) 会员可见会员可见会员可见会员可见18,724,000.009,443,000.00-20,247,000.00-11,056,000.0013,637,000.0025,214,000.00
 递延收入(元) 会员可见会员可见会员可见会员可见-775,000.00-504,000.005,794,000.007,000,000.00--
 经营业务其他项目(元) 会员可见会员可见会员可见会员可见-2,266,000.00-1,398,000.00-2,351,000.00-2,324,000.00-1,762,000.00-347,000.00
 经营活动产生的现金流量净额(元) 会员可见会员可见会员可见会员可见14,170,000.00109,752,000.00-260,375,000.00-164,302,000.00-124,446,000.008,799,000.00
投资活动产生的现金流量:
 购买固定资产支付的现金(元) 会员可见会员可见会员可见会员可见-1,428,000.00-721,000.00-9,470,000.00-8,732,000.00-6,614,000.00-3,059,000.00
 投资支付现金(元) 会员可见会员可见会员可见会员可见-797,509,000.00-326,915,000.00-1,065,911,000.00-697,762,000.00-452,363,000.00-265,627,000.00
 投资业务其他项目(元) 会员可见会员可见会员可见会员可见574,232,000.00229,836,000.001,450,028,000.001,162,594,000.00793,729,000.00386,515,000.00
 投资活动产生的现金流量净额(元) 会员可见会员可见会员可见会员可见-224,705,000.00-97,800,000.00374,647,000.00456,100,000.00334,752,000.00117,829,000.00
融资活动产生的现金流量:
 发行股份(元) 会员可见会员可见会员可见会员可见279,733,000.00280,745,000.0032,721,000.00---
 行使股票期权所得(元) 会员可见会员可见会员可见会员可见25,735,000.0025,189,000.0029,943,000.0023,725,000.0022,169,000.005,404,000.00
 融资活动产生的现金流量净额(元) 会员可见会员可见会员可见会员可见305,468,000.00305,934,000.0062,664,000.0023,725,000.0022,169,000.005,404,000.00
汇率变动影响(元) 会员可见会员可见会员可见会员可见-9,000.00-11,000.0073,000.0012,000.0060,000.0032,000.00
现金及现金等价物期初余额(元) 会员可见会员可见会员可见会员可见401,068,000.00401,068,000.00224,060,000.00224,060,000.00224,060,000.00224,060,000.00
现金及现金等价物增加(减少)额(元) 会员可见会员可见会员可见会员可见94,924,000.00317,875,000.00177,009,000.00315,535,000.00232,535,000.00132,064,000.00
现金及现金等价物期末余额(元) 会员可见会员可见会员可见会员可见495,992,000.00718,943,000.00401,068,000.00539,595,000.00456,595,000.00356,124,000.00
补充资料其他项目(元) --会员可见会员可见3,049,000.004,653,000.001,142,000.00763,000.001,322,000.00715,066,000.00
公告日期 2025-08-042025-05-062025-02-112024-11-052024-08-052024-05-082024-02-212023-11-062023-08-072023-05-08
会计准则 美国会计准则美国会计准则美国会计准则美国会计准则美国会计准则美国会计准则美国会计准则美国会计准则美国会计准则美国会计准则
审计意见
核数师

前瞻产业研究院